Abbott shares rise

Abbott, Reckitt Score First Victory in Baby Formula Trial
Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a baby boy.
Abbott shares rise after securing first win in premature infant formula trial
Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.A jury in St.
Abbott, Mead Johnson secure win in infant formula trial, Reuters reports
Abbott (ABT) and Reckitt Benckiser’s (RBGLY) unit Mead Johnson are not responsible for a young boy’s debilitating intestinal
Abbott, Mead Johnson Win Defense Verdict Over Preemie Infant Formula
In closing arguments on Wednesday, plaintiff's lawyer Timothy Cronin asked jurors for $6 billion in punitive damages.
Abbott, Reckitt Stocks Rise on Baby-Formula Lawsuit Win
Shares of Abbott Laboratories and Reckitt Benckiser rose Friday after the companies won a victory in litigation over the safety of some of their baby-formula products. Abbott shares rose 4% in early New York trading,
Abbott, Reckitt unit defeat claims in baby formula trial
Abbott Laboratories and a unit of Reckitt Benckiser Group were cleared by a jury over claims they hid risks in their premature-infant formulas can cause a bowel disease that severely sickened a baby boy.
Abbott Laboratories Shares Rise After Baby-Formula Verdict
A jury found Abbott Laboratories and Mead Johnson, owned by U.K.-based Reckitt Benckiser, not responsible for a young boy's intestinal disease, the result of a lawsuit that alleged the companies failed to warn that its formula for premature infants increased the risk for a bowel disease.
Abbott, Reckitt unit defeat claims in premature baby formula trial
The decision marks the first victory for the companies as they face more than 1,000 similar cases and previously lost trials, one of which ended with a $500 million verdict.
Abbott and Reckitt unit secure win in infant formula trial
Abbott and Reckitt's unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on Thursday in a lawsuit that accused the companies of failing to warn of the risks of premature baby formulas.
Bloomberg L.P.1d
Reckitt Surges Most in 24 Years After Baby Formula Trial Win
Shares of Reckitt Benckiser Group Plc jumped the most in 24 years following a US jury verdict that cleared it and Abbott ...
Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win
Shares of Abbott Laboratories are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after ...
Jury sides with Abbott Laboratories in ongoing fight over preterm infant formulas
A St. Louis jury handed Abbott Laboratories a win Thursday, deciding that Abbott, another company and a hospital were not ...
Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win
Shares in Reckitt Benckiser topped the Stoxx Europe 600 Index after a U.S. court cleared the company of liability in a case ...